Professor Heerspink focuses on optimizing treatment strategies, finding new CKD therapeutic approaches and personalized medicine. He is Professor of Clinical Trials and Personalized Medicine and a clinical trialist at the Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen and Clinical Pharmacologist University Medical Center Groningen. His expertise includes clinical trial design and methodological aspects and statistical analyses of clinical trials.
Dr. Wheeler’s research focuses on CKD and its complications, specifically those that increase cardiovascular disease burden and/or accelerate kidney failure progression. He heads a clinical research team at the Royal Free Hospital in London and is Professor of Kidney Medicine at University College London. He has been involved in the development of Clinical Practice Guidelines for Kidney Disease: Improving Global Outcomes (KDIGO) and was KDIGO co-chair between 2012 and 2019.
Dr. Kosiborod’s research has a strong focus on the intersection of diabetes and cardiovascular disease. He is Vice President of Research at Saint Luke’s Health System; Director of Cardiometabolic Research and Co-Director of the Haverty Cardiometabolic Center of Excellence at Saint Luke’s Mid America Heart Institute; and Professor of Medicine at the University of Missouri-Kansas City. He is an internationally recognized expert in diabetes and cardiovascular disease, cardiometabolic and cardiorenal syndromes, as well as quality of care and outcomes. He received training in clinical research, epidemiology and health policy through the Robert Wood Johnson Clinical Scholars Program, as well as clinical training in cardiovascular medicine at Yale University School of Medicine.
As a practicing clinician and researcher, Dr. Kosiborod seeks to establish a practical system of implementing adoption of new treatments that have been proven to be life saving into practice in a more timely manner. He continues to be involved in the leadership of numerous clinical trials and multi-center registries, and serve as the Principal Investigator of investigator-initiated, multi-center trials in diabetes and cardiovascular disease, most recently of SGLT2 inhibition.
Meet with George Clinical! Contact us to schedule a time now.
